Robin J. Filshie

St Vincent's Hospital Melbourne
Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas.

Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas.

Journal: Leukemia & lymphoma

Published: November 06, 2025

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Journal: Blood advances

Published: November 18, 2024

Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.

Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.

Journal: Blood advances

Published: June 20, 2024

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.

Journal: Blood

Published: April 12, 2024

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.

Journal: BMJ open

Published: January 18, 2024

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

Journal: The Lancet. Haematology

Published: October 07, 2023

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.

Journal: American journal of hematology

Published: October 21, 2022

Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.

Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.

Journal: Internal medicine journal

Published: September 05, 2022

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.

Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic.

Journal: Leukemia & lymphoma

Published: June 21, 2022

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).

Journal: Leukemia & lymphoma

Published: July 15, 2021

Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.

Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy.

Journal: Leukemia & lymphoma

Published: September 28, 2020

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 31, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026